Capricor Therapeutics, Inc. Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP

FDA extended Capricor Therapeutics' deramiocel review to November 22, 2026, after the company submitted a major amendment with 24-month HOPE-3 study data. HC Wainwright maintained a Neutral rating, citing high regulatory risk. The firm will reassess after more regulatory information is available.

Capricor Therapeutics (CAPR) stock rose 2.6% after the FDA extended its review period for Deramiocel to November 22, 2026, due to new data submission. Shares initially surged to $8.015 but retreated amid broader market declines and regulatory concerns. Analysts have mixed views, with Cantor Fitzgerald targeting $28. The stock's 52-week range is $2.96 to $40.37.

Capricor Therapeutics (CAPR) shares rose 29% after the FDA extended the review period for its Deramiocel BLA to November 22, 2026. The extension follows the submission of additional Phase 3 HOPE-3 data supporting a refined indication for Duchenne muscular dystrophy. The FDA accepted the amendment, citing significant unmet medical need.

Capricor Therapeutics (CAPR) faces a class action lawsuit for alleged securities violations. The DJS Law Group claims the company made false statements regarding its clinical data analysis and FDA agreement for Deramiocel. Shareholders who bought shares between December 17, 2025, and July 26, 2026, are encouraged to contact the firm by September 28, 2026, to discuss potential recovery.

Capricor Therapeutics (CAPR) faces a securities fraud class action lawsuit for alleged misstatements about its lead product candidate's statistical analysis plan and FDA compliance. The lawsuit covers investments between December 17, 2025, and July 26, 2026, with a deadline to seek lead plaintiff status on September 28, 2026. The FDA's briefing documents revealed unapproved changes to the analysis plan, causing CAPR's stock to drop 64% on July 27, 2026.

A class action lawsuit was filed against Capricor Therapeutics (NASDAQ: CAPR) by investors who purchased shares between December 17, 2025, and July 26, 2026. The lawsuit alleges securities fraud, claiming the company misrepresented its lead product candidate's statistical analysis plan and FDA compliance. The FDA's briefing documents revealed disagreements with Capricor's changes, causing the stock to drop 64%. Investors have until September 28, 2026, to seek lead plaintiff status.